Element Capital Management LLC Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• Element Capital Management LLC invested approximately $2.78 million in Edwards Lifesciences Corporation, acquiring 38,369 shares, making it the firm's 24th largest holding.
• Multiple hedge funds have increased their positions in Edwards Lifesciences, with Jennison Associates LLC raising its stake by 34.3% in the first quarter.
• Analysts have set a consensus price target of $85.90 for Edwards Lifesciences, with most ratings being either "buy" or "hold".

Element Capital Management LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund bought 38,369 shares of the medical research company's stock, valued at approximately $2,781,000. Edwards Lifesciences accounts for 0.7% of Element Capital Management LLC's investment portfolio, making the stock its 24th largest holding.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jennison Associates LLC increased its position in shares of Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Brown Advisory Inc. raised its holdings in shares of Edwards Lifesciences by 7.6% during the fourth quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after acquiring an additional 575,699 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after acquiring an additional 652,923 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Edwards Lifesciences by 8.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after acquiring an additional 513,468 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Edwards Lifesciences by 21.8% during the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after acquiring an additional 1,165,845 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EW. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Royal Bank Of Canada boosted their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Citigroup reiterated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Evercore ISI boosted their price target on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a research report on Friday, July 25th. Finally, Morgan Stanley boosted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.90.

Insider Activity

In related news, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president directly owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 26,084 shares of company stock valued at $2,010,382 over the last three months. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 3.0%

EW stock traded up $2.3440 during trading on Wednesday, reaching $81.2740. 5,058,602 shares of the stock were exchanged, compared to its average volume of 4,834,787. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $77.35 and a 200-day moving average price of $74.54. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The firm has a market capitalization of $47.72 billion, a price-to-earnings ratio of 11.69, a P/E/G ratio of 3.81 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the firm earned $0.70 earnings per share. Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.